|
gptkbp:instanceOf
|
gptkb:antibiotic
|
|
gptkbp:administeredBy
|
intramuscular
inhalation
intravenous
ophthalmic
|
|
gptkbp:ATCCode
|
gptkb:J01GB01
|
|
gptkbp:CASNumber
|
32986-56-4
|
|
gptkbp:contraindication
|
hypersensitivity to aminoglycosides
|
|
gptkbp:discoveredBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:discoveredIn
|
1967
|
|
gptkbp:eliminationHalfLife
|
2-3 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasMolecularFormula
|
C18H37N5O9
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tobramycin
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial protein synthesis
|
|
gptkbp:metabolism
|
not metabolized
|
|
gptkbp:origin
|
gptkb:Streptomyces_tenebrarius
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
<30%
|
|
gptkbp:routeOfAdministration
|
IV
IM
inhalation
ophthalmic
|
|
gptkbp:sideEffect
|
nephrotoxicity
ototoxicity
neuromuscular blockade
|
|
gptkbp:synonym
|
gptkb:Tobrex
gptkb:Nebcin
|
|
gptkbp:treatment
|
gptkb:Pseudomonas_aeruginosa
cystic fibrosis (lung infections)
|
|
gptkbp:usedFor
|
bacterial infections
|
|
gptkbp:bfsParent
|
gptkb:Aminoglycosides
gptkb:Tobradex
gptkb:Tobrex
|
|
gptkbp:bfsLayer
|
5
|